Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Irinotecan as First-Line Therapy for Extensive Stage SCLC
NCT00469898Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Dec 2003
- Primary completion
- Jul 2008
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in small cell lung cancer (SCLC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Patient Response at 1.66 months. Started Dec 2003; status: completed.
02
Drugs
carboplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00469898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00469898.